You are here

Development of Human Monoclonal Antibody Therapeutic against Klebsiella pneumoniae Infection

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH21P0031
Agency Tracking Number: H202-003-0037
Amount: $249,562.98
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHA202-003
Solicitation Number: 20.2
Timeline
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-02-10
Award End Date (Contract End Date): 2021-09-09
Small Business Information
1515 West 2200 South Suite F
Salt Lake City, UT 84119-1441
United States
DUNS: 829431076
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Robert Price
 (801) 915-7973
 robert@tekholding.com
Business Contact
 Mukund Karanjikar
Phone: (801) 953-1047
Email: mukund@tekholding.com
Research Institution
N/A
Abstract

Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we present an optimized workflow to yield high affinity monoclonal antibody candidates against surface antigens from common infectious disease which is increasingly antibiotic resistant.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government